COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective

• DOI: 10.1016/j.breast.2021.10.012
• Publication Date: 2021-10-29T15:42:54Z
• Authors: Marie Forster; Rachel Wuerstlein; Alexander Koenig; Niklas Amann; Susanne Beyer; Till Kaltofen; Tom Degenhardt; Alexander Burges; Fabian Trillsch; Sven Mahner; Nadia Harbeck; Anca Chelariu-Raicu
• Keywords: COVID-19 Vaccines; Genital Neoplasms, Female; SARS-CoV-2; Vaccination; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; COVID-19; Cancer patients; Breast Neoplasms; 3. Good health; 03 medical and health sciences; Breast cancer; 0302 clinical medicine; Gynecological cancer; Humans; Original Article; Female; RC254-282; 2019-nCoV Vaccine mRNA-1273; Aged

The side effects of systemic cancer therapy and the lack clinical data on safety efficacy COVID-19 vaccination in patients cause uncertainty among about whether to get vaccinated or not. Here, we evaluated attitude towards with breast gynecological undergoing therapy.Since March 15th, 2021, who received one approved vaccines were routinely interviewed immediate late effects. Clinical parameters such as current therapy, time interval between administration vaccination, changes schedule due documented. collected analyzed de-identified a part routine quality assurance.By July 27th, 218 (74.3% patients) had two vaccine doses, 112 both doses: 77.5% Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) 5.9% Vaccine Moderna. an acceptable profile self-limiting local adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after second dose less frequently older >55 years. No vaccine-related serious events reported, only limited observed.Breast gynecologic tolerate while without any additional beyond those reported general population.